SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

05 Aug 2025 Evaluate
A minor change in the total revenue was seen in the June 2025 quarter. The total revenue for the quarter stood at Rs. 10388.35 millions against Rs. 10120.24 millions during year ago period.The Company has registered profit of Rs. 2692.58  millions for the quarter ended June 2025, a growth of 20.79%  over Rs. 2229.21 millions millions achieved in the corresponding quarter of last year.Operating Profit saw a handsome growth to 4135.86 millions from 3420.43 millions in the quarter ended June 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 10388.35 10120.24 2.65 10388.35 10120.24 2.65 41161.49 41674.28 -1.23
Other Income 547.41 484.90 12.89 547.41 484.90 12.89 2150.75 1666.66 29.05
PBIDT 4135.86 3420.43 20.92 4135.86 3420.43 20.92 16576.93 15754.47 5.22
Interest 74.35 9.11 716.14 74.35 9.11 716.14 228.37 78.43 191.18
PBDT 4061.51 3411.32 19.06 4061.51 3411.32 19.06 16348.56 15676.04 4.29
Depreciation 437.68 408.17 7.23 437.68 408.17 7.23 1692.71 1621.07 4.42
PBT 3623.83 3003.15 20.67 3623.83 3003.15 20.67 14655.85 14054.97 4.28
TAX 931.25 773.94 20.33 931.25 773.94 20.33 3758.32 3621.72 3.77
Deferred Tax -1.46 11.82 -112.35 -1.46 11.82 -112.35 91.24 246.84 -63.04
PAT 2692.58 2229.21 20.79 2692.58 2229.21 20.79 10897.53 10433.25 4.45
Equity 164.76 164.75 0.01 164.76 164.75 0.01 164.76 164.71 0.03
PBIDTM(%) 39.81 33.80 17.80 39.81 33.80 17.80 40.27 37.80 6.53

Gland Pharma Share Price

1731.30 -24.70 (-1.41%)
16-Apr-2026 11:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1219.55
Cipla 1230.95
Zydus Lifesciences 938.80
Lupin 2303.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×